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Background: Little is known about the spectrum of underlying disorders in dogs with unilateral
masticatory muscle (MM) atrophy.
Objectives: To evaluate the clinical presentation, magnetic resonance imaging (MRI) findings,
and outcome of dogs with unilateral MM atrophy.
Animals: Sixty-three client-owned dogs.
Methods: The medical database was retrospectively reviewed for dogs that underwent MRI for
evaluation of unilateral MM atrophy. Imaging studies were reviewed and follow-up information
was obtained from telephone interviews.
Results: Presumptive trigeminal nerve sheath tumor (pTNST) was diagnosed in 30 dogs (47.6%);
survival time varied from 1 day to 21 months (median, 5 months). Other extra-axial mass lesions
were observed in 13 dogs (20.6%); survival time varied from 6 days to 25 months (median,
2.5 months). In 18 dogs (28.6%), no abnormalities were observed on MRI; neurological signs
only progressed in 1 dog. Diagnosis had a significant influence on the type of neurological
abnormalities, with additional neurological deficits observed in most dogs with pTNST and in all
dogs with other extra-axial mass lesions. Diagnosis had a significant effect on euthanasia at the
time of diagnosis and likelihood of neurological deterioration. Dogs with mass lesions were more
likely to be euthanized or experience neurological deterioration, whereas these outcomes
occurred less often in dogs in which no causative lesion could be identified.
Conclusions and Clinical Importance: Trigeminal nerve sheath tumors should not be considered
the only cause of unilateral MM atrophy. Our results illustrate the importance of performing a
neurological examination and MRI when evaluating dogs with unilateral MM atrophy.
KEYWORDS
cranial nerves, facial asymmetry, neuritis, trigeminal nerve sheath tumor
1 | INTRODUCTION
The muscles of mastication are responsible for movement of the man-
dible during prehension and mastication of food. They include the
temporalis, masseter, pterygoideus, mylohyoideus, and digastricus
muscles. The mandibular branch of the trigeminal nerve innervates
each of these with the exception of the caudal belly of the digastricus,
which receives its innervation from the facial nerve.1 Bilateral mastica-
tory muscle (MM) atrophy occurs relatively commonly in dogs and can
be caused by several underlying disease processes. Comparatively,
facial asymmetry caused by unilateral MM atrophy is observed less
frequently and is associated with a limited number of differential diag-
noses.2 Neoplasia of the trigeminal nerve is thought to be the most
common cause of unilateral MM atrophy.2,3 By far the most common
type of tumor affecting the trigeminal nerve is malignant nerve sheath
tumor with other tumors, such as lymphoma, occurring less com-
monly.4 Trigeminal nerve sheath tumors (TNST) are an uncommon
intracranial neoplasm in dogs, for which unilateral MM atrophy
Abbreviations: CSF, cerebrospinal fluid; MM, masticatory muscle; MRI, mag-
netic resonance imaging; PLR, pupillary light reflex; pTNST, presumptive trigem-
inal nerve sheath tumor; TNST, trigeminal nerve sheath tumor.
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appears to be a consistent clinical feature.3 The nature of additional
clinical signs seen is reflected by the local effects of trigeminal nerve
dysfunction and those secondary to potential brainstem compression.
Reported findings in animals with TNST therefore include decreased
facial sensation, facial rubbing, absent palpebral reflex, decreased cor-
neal sensation, ocular pathology, decreased menace response, torti-
collis, ipsilateral Horner's syndrome, enophthalmia, and paradoxical
vestibular syndrome.3,5–8 The auditory tube is controlled by the tensor
tympani and tensor veli palatini muscles innervated by the trigeminal
nerve and the levator veli palatini and salpingopharyngeus muscles
innervated by the vagus nerve. Trigeminal nerve lesions therefore also
have been associated with auditory tube dysfunction and middle ear
effusion in dogs.9–11 These neoplasms typically affect older dogs and
are considered progressive.3,7,9 Other differential diagnoses for unilat-
eral MM atrophy include neuropathies such as trigeminal neuritis,6 idi-
opathic trigeminal neuropathy,5 and also could include myopathies,
traumatic injury, or extension of other extra-axial mass lesions.12 To
date, little is known about the spectrum, distribution, progression, and
outcome of underlying causes for unilateral MM atrophy. Our aims
therefore were to investigate the various etiologies, presenting signs,
magnetic resonance imaging (MRI) findings, and outcome of dogs pre-
senting with unilateral MM atrophy. The results of our study may help
guide clinical investigations, as well as improve understanding of the
disease progression both for accurate prognostication, treatment
selection, and management of owner expectations.
2 | MATERIALS AND METHODS
The study was approved by the local clinical research ethical review
board (URN: M2016 0088). The electronic medical databases of 2 aca-
demic referral hospitals were searched from June 2003 to October
2016 for dogs presented with unilateral MM atrophy as their predomi-
nant clinical sign. Dogs were included in the study if: (1) they were
referred for further investigation of unilateral MM atrophy as the pre-
dominant clinical sign, (2) complete medical records were available for
review, (3) facial asymmetry with unilateral MM atrophy was confirmed
on clinical examination, and (4) MRI of the head was performed and
images were available for review. Histopathological confirmation was
not necessary to be included in this study. Information retrieved from
the clinical records included signalment, clinical signs, neurological
examination findings, results of diagnostic investigations, and any treat-
ment received. Dogs were excluded if clinical records or imaging studies
were unavailable for review or if unilateral MM atrophy was incidentally
observed or not the predominant clinical indication for referral. All medi-
cal files and imaging studies were reviewed by a board-certified neurol-
ogist (Steven De Decker) to evaluate if potential cases could be
included or should be excluded. After reviewing the MRI studies,
included dogs were divided into 4 diagnostic categories: (1) presumptive
trigeminal nerve sheath tumor (pTNST); (2) other extra-axial mass
lesions affecting the cerebellopontine angle or petrosal part of the tem-
poral bone; (3) unilateral MM atrophy with no causative lesion identified
on MRI; and (4) dogs that could not be classified into any of the above
categories (Figure 1).
For the purpose of the study, pTNST was defined as a unilateral,
well-circumscribed, extra-axial, homogenously contrast-enhancing
mass at the level of the pons, or associated with 1 or more branches
of the trigeminal nerve within the caudal cranial fossa, middle cranial
fossa, or in the extracranial peripheral division of its branches or
both.3,6,9,11 Other extra-axial mass lesions affecting the cerebellopon-
tine angle or petrosal part of the temporal bone, but not arising from
the trigeminal nerve or ganglion, were classified in a separate group.
Magnetic resonance imaging of the head of each dog was per-
formed under general anesthesia using a permanent 1.5T Magnet
(Intera, Philips Medical Systems, Eindhoven, the Netherlands, or Sie-
mens Magnetom Essenza, Frimley, United Kingdom). The MRI
sequences included a minimum of T2-weighted (TW2; repetition time
[TR] [ms], echo time [TE] [ms] 3333/110) sagittal and transverse images
and transverse fluid attenuation inversion recovery images (FLAIR;
TR/TE, 6000/120). Transverse plane T1-weighted (T1W) images
(TR/TE, 515/15) were acquired before and after IV injection of gadolin-
ium contrast material (0.1 mL/kg gadoterate meglumine, Dotarem,
Guerbet, Milton Keynes, England). Slice thickness was 3.5 mm in all
planes with an interslice gap of 0.9 mm in the sagittal and 1 mm in the
transverse planes. Images of dogs with pTNST were reviewed by a
board-certified neurologist (Elsa Beltran), who did not perform the initial
evaluation of the imaging studies, using Osirix DICOM viewer (Osirix
Foundation, V.5.5.2 Geneva, Switzerland). This reviewer was aware of
the suspected diagnosis of pTNST in each case, but was blinded to the
signalment, and general physical and neurological examination findings.
FIGURE 1 T1-weighted transverse images after IV administration of gadolinium contrast material in 3 dogs presenting for further evaluation of
right-sided unilateral masticatory muscle atrophy. Atrophied muscles are indicated with asterisk. A, Presumptive trigeminal nerve sheath tumor
(arrow). B, An extra-axial mass affecting the cerebellopontine angle (arrow). C, No abnormalities were detected on magnetic resonance imaging
with the exception of unilateral masticatory muscle atrophy
2 MILODOWSKI ET AL.
The trigeminal nerve was evaluated using 5 variables as previously
reported for oculomotor nerve dysfunction13: (1) enlargement (mild or
marked); (2) intensity on T2W and T1W images; (3) degree of contrast
enhancement (none, mild, or marked); (4) pattern of contrast enhance-
ment (focal or diffuse and homogenous or heterogeneous enhance-
ment); and (5) anatomical region of the lesion. The presence of middle
ear effusion was recorded for all included dogs.
Follow-up to discharge was collated from both referral centers, and
subsequent follow-up from the referring veterinarian also was obtained.
Initially, the referring veterinary surgeon of each animal was contacted
by telephone. For dogs that were deceased, the date, cause of death,
and last recorded neurological status at the time of death were
recorded. In accordance with local ethical and welfare committee guide-
lines, owners of deceased dogs were not contacted further. For all dogs
that were presumed to be still alive at the time of study enrollment, a
letter was sent to the owner outlining the study aims along with a stan-
dardized questionnaire before being contacted for a telephone inter-
view. Owners were asked to comment on neurological progression and
improvement of clinical signs. Telephone interviews were performed by
1 of 2 investigators (Emily J. Milodowski for cases from the Royal veter-
inary College and PA-B for cases from Glasgow University). The ques-
tionnaire was approved by the local ethics and welfare committee
(Supporting Information Questionnaire).
Statistical analysis was performed by commercial statistical soft-
ware (GraphPad prism 7, Version 7.0a for Mac OS X, GraphPad
Software, La Jolla, California). Dogs that were euthanized at the time
of original diagnosis, or that were lost to follow-up, were censored
from statistical analysis from the point of last contact. Overall survival
time was calculated from the time of MRI diagnosis. Dogs in the
unclassified group were excluded from statistical analysis. Data for
age, duration of clinical signs, and survival time were assessed for
normality by the Shapiro-Wilk normality test. Continuous data was
compared by Kruskall-Wallis tests and categorical data were evalu-
ated using chi-square or Fisher's exact tests. The occurrence of neuro-
logical abnormalities detected at the time of presentation was
compared with a 2-way analysis of variance (ANOVA). A value of
P < .05 was considered statistically significant. Significance level for
multiple comparisons was adjusted by Bonferroni's method.
3 | RESULTS
Sixty-three dogs were included in the study. Unilateral MM atrophy
was associated with pTNST in 30 dogs (47.6%), other extra-axial mass
lesions affecting the cerebellopontine angle or petrosal part of the
temporal bone in 13 dogs (20.6%), and no causative lesion was identi-
fied in 18 dogs (28.6%) and 2 dogs could not be classified into any of
the above categories. Both of these cases presented with unilateral
MM atrophy but neurological examination also identified sciatic neu-
ropathy. The relationship between both conditions was unknown.
3.1 | Dogs with suspected TNST
The 30 dogs diagnosed with pTNST included 14 female (7 neutered)
and 16 male (8 neutered) dogs. The median age at presentation was
9 years 3 months (range 1 year 6 months to 13 years). Breeds
included Labrador Retriever (n = 5), Boxer, English Bull Terrier, West
Highland White Terrier, Staffordshire Bull Terrier (n = 2 for each);
11 breeds were represented by 1 dog and 6 dogs were crossbreeds.
Left-sided unilateral MM atrophy was seen in 17 dogs and right-
sided atrophy in 13 dogs. Duration of clinical signs varied from 10 days
to 2 years before presentation (median, 2.75 months). Masticatory
muscle atrophy was the only clinical sign in 5 dogs. Neurological
examination identified additional abnormalities in the remaining
25 dogs (83%) and included enophthalmos (n = 12 dogs), facial hyper-
esthesia (n = 2), decreased or absent ipsilateral palpebral reflex
(n = 10), head tilt (n = 6) opposite to the side of MM atrophy in
2 dogs, generalized ataxia (n = 6), proprioceptive deficits (n = 6), cer-
vical hyperesthesia (n = 6), obtundation (n = 5), decreased ipsilateral
menace response (n = 5), positional strabismus (n = 5), ipsilateral Hor-
ner's syndrome (n = 4), decreased gag reflex (n = 4), decreased pupil-
lary light reflex (PLR; n = 1), nystagmus (n = 1), and tetraparesis
(n = 1). A Schirmer’s tear test identified decreased tear production in
2 dogs. Magnetic resonance imaging disclosed middle ear effusion
in 18 dogs (60%). The effusion was ipsilateral to the MM atrophy in
16 dogs, whereas bilateral effusion was observed in 2 dogs. The MRI
appearance of the pTNSTs was recorded (Table 1). In 9 of 30 dogs,
cerebrospinal fluid (CSF) analysis using CSF from cisternal puncture
was performed; total nucleated cell count was normal (<5/μl) in all
samples, but 2 dogs showed increased CSF protein concentrations
(0.49 g/L and 0.54 g/L; reference interval, <0.3 g/L).
Three dogs were euthanized at the time of diagnosis without
treatment attempted because of the severity of clinical signs and
anticipated poor prognosis. Nine of the remaining 27 dogs did not
receive any specific treatment. Treatment in the remaining 18 dogs
varied and included prednisolone alone (n = 8 dogs); prednisolone in
combination with radiotherapy (n = 2) or gabapentin (n = 1); meloxi-
cam with cyclophosphamide (n = 2); meloxicam alone (n = 1);
hydroxyurea alone (n = 3); and hydroxyurea in combination with
TABLE 1 Magnetic resonance imaging characteristics of 30 dogs
diagnosed with presumptive trigeminal nerve sheath tumor
Evaluated variable Finding Number of dogs
Trigeminal nerve
enlargement
Marked 23
Mild 7
Position CCF + TC + MCF + EC 18
CCF + TC + MCF 6
TC + MCF 3
TC + MCF + EC 2
MCF 1
T2-weighted intensity Hyperintense 20
Isointense 9
Hypointense 1
T1-weighted intensity Isointense 17
Hypointense 13
Contrast enhancement Marked 23
Mild 7
Abbreviations: CCF, caudal cranial fossa; EC, extra-cranial portion; MCF,
middle cranial fossa; TC, trigeminal canal.
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lomustine (n = 1). Outcome data were available for 22 of the 27 dogs.
Twenty-one of these 22 dogs were dead at the time of study enroll-
ment, whereas 1 dog was still alive despite progression of vestibular
signs 7 months after diagnosis. Two dogs were euthanized in the first
7 days after treatment was initiated. They were euthanized because
of progression of clinical signs, and both had received prednisolone
after diagnosis. Seventeen other dogs were euthanized between
9 days and 24 months (median, 8 months) after diagnosis of pTNST
because of continuous progression of neurological signs. Progression
of neurological signs included development of vestibular signs in
13 dogs, loss of facial sensation (n = 5), loss of corneal reflex (n = 3),
collapse episodes (n = 2), seizures (n = 2), Horner's syndrome (n = 2),
decreased gag reflex and dysphagia (n = 2), obtundation (n = 1), ton-
gue deviation (n = 1), and cervical hyperesthesia (n = 1). Two dogs
were euthanized for unrelated causes, 1 because of developing persis-
tent blindness after cataract surgery 5 months after diagnosis, the
other because of severe osteoarthritis 21 months after diagnosis.
Neither dog was reported to have experienced neurological deteriora-
tion after diagnosis. For the purpose of the study, these 2 dogs were
included in the survival analysis. Overall survival time for this group
varied from 1 day to 1 year and 9 months after diagnosis (median
5 months).
3.1.1 | Dogs with other extra-axial mass lesions affecting
the cerebellopontine angle or petrosal part of the
temporal bone
Of the 13 dogs with other extra-axial mass lesions, 6 were females
(3 neutered) and 7 were neutered males. Median age at diagnosis was
7 years 5 months (range 5 years 1 month to 11 years 5 months). This
group included 2 Labrador Retrievers, 2 Boxers, 5 breeds were repre-
sented by 1 dog, and 4 dogs were cross breeds. The duration of clini-
cal signs varied from 2 weeks to 1 year (median 1 month). Six dogs
had left-sided and 7 dogs had right-sided MM atrophy. All dogs
(100%) had additional abnormalities on neurological examination
including decreased palpebral reflex (n = 5 dogs), head tilt (n = 5),
which was toward the affected side in 4 dogs, generalized ataxia
(n = 5), decreased mentation (n = 4), decreased tear production
(n = 4), proprioceptive deficits (n = 4), decreased menace response
(n = 3), Horner's syndrome (n = 3), decreased corneal reflex (n = 2),
strabismus (n = 2), cervical hyperesthesia (n = 2), nystagmus (n = 2),
ipsilateral facial hyperesthesia (n = 1), and abnormal PLR (n = 1). Two
dogs had corneal ulceration.
Assessment of MRI indicated extra-axial mass lesions ipsilateral to
the MM atrophy, which did not arise from the trigeminal nerve or gan-
glion. In 9 cases, an extra-axial homogenously contrast-enhancing
mass lesion was located in the cerebellopontine angle. The most likely
differential diagnoses for these dogs were considered to be meningi-
oma and histiocytic sarcoma. Histopathological examination resulted
in a diagnosis of histiocytic sarcoma in 1 dog. In the remaining 4 cases,
the lesion affected primarily the petrosal portion of the temporal
bone. The most likely differential diagnosis for these 4 dogs was con-
sidered to be a tumor of bone, such as osteosarcoma. Four cases
(31%) were observed to have ipsilateral middle ear effusion. In 1 dog,
CSF analysis using CSF from cisternal puncture was performed, and
the results were within normal limits.
Six dogs were euthanized at the time of diagnosis without treat-
ment because of the nature of the diagnosis and severity of clinical
signs. Follow-up data were available for 6 of the remaining 7 cases.
One dog did not receive any specific type of treatment and was
euthanized 6 days after diagnosis because of progression of clinical
signs. Three dogs were treated with prednisolone alone; 1 was eutha-
nized after 7 days, 1 survived for 2 months, and the remaining dog
survived for 6 months after diagnosis. All 3 dogs experienced progres-
sion of neurological signs before euthanasia, including deterioration in
mentation and vestibular signs. One dog was treated with a combina-
tion of prednisolone, hydroxyurea, and lomustine. This dog was eutha-
nized 3 months later because of progression of tetraparesis and
generalized ataxia. The final dog was treated with a combination of
prednisolone, hydroxyurea, and radiotherapy. This dog experienced
neurological deterioration beginning 6 months after diagnosis. The
dog developed Horner's syndrome, decreased facial sensation, and
head tilt, and was euthanized 25 months after diagnosis. Overall sur-
vival time for this group varied therefore from 6 days to 25 months
after diagnosis (median, 2.5 months).
3.1.2 | Dogs without an underlying lesion detected
on MRI
In 18 of the 63 dogs, no identifiable lesion was detected on MRI of
the head except for unilateral MM atrophy. This group consisted of
14 males (4 neutered) and 4 females (2 neutered). Median age at diag-
nosis was 7 years 10 months (range, 2 years 10 months to 11 years
1 month). Breeds included Staffordshire Bull Terrier (n = 5 dogs), Lab-
rador Retriever (n = 4), 7 breeds were represented by 1 dog, and
2 dogs were cross breeds. Twelve dogs had left-sided and 6 had right-
sided MM atrophy. Duration of clinical signs before presentation var-
ied from 1 day to 1 year (median, 2 months). In 9 dogs, facial asymme-
try as a result of MM atrophy was the only clinical sign detected.
Neurological examination disclosed additional abnormalities in the
remaining 9 dogs (50%) and included Horner’ syndrome (n = 5 dogs),
decreased or absent facial sensation (n = 3), decreased corneal sensa-
tion (n = 2), decreased palpebral reflex (n = 2), and decreased menace
response (n = 1). A Schirmer’s tear test identified decreased tear pro-
duction in 1 dog.
Assessment of MRI findings indicated middle ear effusion in
3 dogs; 1 dog had bilateral effusion, 1 dog had ipsilateral effusion,
whereas the effusion was contralateral to the MM atrophy in the 3rd
dog. In 12 dogs, CSF analysis using CSF obtained by cisternal puncture
was performed; total nucleated cell count was mildly increased in
1 case (8 cells/μl; reference interval, <5 cells/μl). In 1 dog, CSF protein
concentration was increased with normal cell count (0.62 g/L; refer-
ence interval, <0.3 g/L). Electromyography was performed in 4 dogs
and disclosed positive sharp waves in the affected muscles, but no
abnormalities were seen in unaffected muscles. Testing for type 2M
antibodies was performed in 8 dogs, including the 4 dogs that under-
went electromyography. All had negative results.
One dog was euthanized at the time of diagnosis at the owner's
request because of a potentially poor prognosis. This dog also had
decreased facial sensation, loss of palpebral reflex, and ipsilateral Hor-
ner's syndrome. Of the remaining 17 dogs, 9 received treatment and
8 did not receive treatment. Treatment included prednisolone alone
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(n = 4 dogs), prednisolone in combination with cyclophosphamide
(n = 1), gabapentin (n = 1), gabapentin and radiotherapy (n = 1), or
hydroxyurea alone (n = 1). One dog received a combination of neomy-
cin, polymyxin, and dexamethasone ophthalmic ointment and cyclospor-
ine A ointment for ocular pathology and decreased tear production, but
no further treatment specifically related to MM atrophy. Four dogs
were lost to follow-up and of the remaining 13 dogs, 8 were dead
(median survival time, 25 months; range, 7 days to 65 months), and
5 remained alive at the time of study enrollment (at 18, 33, 35, 36, and
54 months after diagnosis). Of the dogs that were dead, only 1 was
euthanized because of neurological disease. This dog did not experience
progression of clinical signs after diagnosis until developing progres-
sively decreased mentation and nonambulatory tetraparesis 38 months
after diagnosis. No further diagnostic tests were performed before
euthanasia and this dog was treated with prednisolone, gabapentin, and
radiotherapy after diagnostic tests for unilateral MM atrophy were per-
formed. It is therefore unclear if this dog was euthanized for reasons
related to the initial presentation of unilateral MM atrophy. The remain-
ing 7 dogs died or were euthanized for unrelated reasons without fur-
ther progression of neurological signs.
Of the 5 dogs still alive at the time of data collection, none had
experienced progression of neurological signs. In 2 dogs, the MM
atrophy resolved without treatment. Another dog retained persistent
stable facial asymmetry after discharge. In the 2 remaining dogs, uni-
lateral MM muscle atrophy progressed after initial clinical presenta-
tion. One of these dogs did not receive any treatment, whereas the
other dog developed bilateral MM atrophy while being treated with
prednisolone.
3.2 | Dogs that could not be classified into groups
Two dogs were presented with unilateral MM atrophy and concurrent
sciatic neuropathy of the contralateral limb. No abnormalities of the
lumbosacral area, trigeminal nerves, cerebellopontine area, or petrosal
part of the temporal bone were identified on MRI. The 1st dog was a
7-year 1-month-old male neutered cross breed, and improved with
treatment using gabapentin and meloxicam. The dog was alive at the
time of data collection, 47 months after diagnosis. The 2nd dog was
an 8 year 2-months-old male intact Labrador Retriever. This dog
received multiple treatments with vincristine, cyclophosphamide,
prednisolone, and cytosine arabinoside because of suspected lym-
phoma. Resolution of unilateral MM atrophy was recorded over
12 months, but sciatic deficits were reported persistently over the
next 3 years. This dog was euthanized 50 months after diagnosis.
Necropsy identified generalized peripheral neuropathy, with the right
sciatic nerve most affected. No inflammatory or neoplastic cells were
detected in the trigeminal or sciatic nerve.
3.3 | Comparison between groups
Diagnosis had a significant influence on the type of abnormalities
detected on neurological examination. Dogs with other extra-axial
mass lesions had head tilt and ataxia significantly more often (P = .02
for both) compared to dogs without an underlying cause identified on
MRI. No significant differences were observed between both groups
(dogs with other extra-axial mass lesions and dogs in which no abnor-
malities were detected) and dogs with pTNST (P > .05). Diagnosis had
a significant influence on the occurrence of middle ear effusion
(P = .008). Dogs with pTNST were more likely to have middle ear
effusion compared to dogs with no causative lesion observed on MRI
(P = .003). No significant differences were found between dogs with
other extra-axial mass lesions and dogs with pTNST or between dogs
with other extra-axial mass lesions and dogs in which no causative
lesion was observed on MRI (P > .05). Diagnosis significantly influ-
enced whether or not treatment was attempted (P = .004). Dogs diag-
nosed with other extra-axial mass lesions were more likely to be
euthanized at the time of diagnosis compared to either the pTNST
group (P = .01) or those with no causative lesion identified on MRI
(P = .01). No significant difference was found between dogs with
pTNST and those in which no underlying cause could be identified
(P > .05). Diagnosis significantly influenced the likelihood of neurolog-
ical deterioration after diagnosis (P = .0007). Neurological deteriora-
tion occurred significantly less often in dogs in which no causative
lesion could be identified on MRI compared to dogs with pTNST
(P = .006) and other extra-axial mass lesions (P = .003). No significant
difference was found for the likelihood of neurological deterioration
between dogs with pTNST and other extra-axial mass lesions. Diagno-
sis did not have a significant influence on any of the other evaluated
variables (P > .02; Bonferroni correction for multiple comparisons).
4 | DISCUSSION
We evaluated the spectrum of clinical characteristics, progression, and
outcome of different underlying causes of unilateral MM atrophy in
dogs. Our results indicate that pTNST should be considered the most
common cause of unilateral MM atrophy, representing almost half of
the dogs included in this study, but other diagnoses constituted over
half of the cases. These included other extra-axial masses not arising
from the trigeminal nerve, whereas in 28.6% of cases no causative
lesion was observed on MRI studies of the head. This finding suggests
that, although an important differential diagnosis, TNST should not be
considered the only cause of unilateral MM atrophy. Our results fur-
ther suggest that unilateral MM atrophy can be caused by a variety of
underlying benign and malignant conditions. This finding emphasizes
the importance of making as accurate as possible a diagnosis by per-
forming a complete neurological examination in combination with
advanced diagnostic imaging in dogs presenting with unilateral MM
atrophy. Although all included dogs were presented with unilateral
MM as their predominant clinical sign, neurological examination iden-
tified additional abnormalities in most dogs with pTNST and in all dogs
with other extra-axial mass lesions. Signs of intracranial involvement
including head tilt, ataxia, proprioceptive deficits, and obtundation
commonly were reported in these groups of dogs. Alternatively, in half
of dogs with no causative lesion observed on MRI, neurological exami-
nation did not identify any additional abnormalities, and neurological
deficits always were limited to the trigeminal nerve or neural struc-
tures in close proximity of the trigeminal nerve, such as the sympa-
thetic or facial nerve. Intracranial signs such as head tilt, ataxia,
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proprioceptive deficits, or obtundation were not observed in this
group of dogs.
As expected, pTNST was the most common cause of unilateral
MM atrophy in our study population. Observed clinical signs, neuro-
logical deficits, and MRI findings were similar to those previously
reported.3,7,9 Although recent studies have focused on clinical out-
comes after advanced treatment strategies, including stereotactic
radiotherapy7,9 and volumetric-modulated arc radiotherapy,14 the nat-
ural progression and survival of dogs with TNST after conservative
treatment has rarely been reported. Although 2 of 27 dogs in which
treatment was attempted underwent radiotherapy, the remaining
25 dogs included in our study received conservative medical treat-
ment or no specific treatment at all. The median survival time of
4 dogs treated conservatively was 12 months in 1 study (range,
5-21 months),3 whereas the median survival time of 10 dogs was only
12 days in a more recent study (range, 1-577 days), with 40% of con-
servatively treated dogs being alive at 1 year after diagnosis.9 In
agreement with these findings, the median survival time in our study
was 5 months and ranged from 1 day to 21 months. In agreement
with previous reports, reliable assessment of outcome was compli-
cated by variation in clinical presentation, MRI findings, and type of
medical management, and also because several dogs were euthanized
at the time of or soon after diagnosis.3,9 Although the prognosis of
dogs with pTNST is poor, it is difficult to accurately predict the out-
come and survival time of dogs treated conservatively for pTNST. In
agreement with previous studies,7,9 progression of clinical signs was
characterized by progressive brainstem compression or other central
nervous system signs, such as vestibular signs, multiple cranial nerve
deficits, seizures, or obtundation.
Our results suggest that other extra-axial mass lesions affecting
the cerebellopontine angle or petrosal portion of the temporal bone
should be considered as important differential diagnoses for unilateral
MM atrophy in dogs. Lesions producing trigeminal motor nerve dys-
function and subsequent MM atrophy may occur anywhere along the
course of the trigeminal nerve from its motor nucleus in the pons to
its distal peripheral nerve endings. The motor nucleus of the trigeminal
nerve is found at the level of the middle and rostral cerebellar pedun-
cles just rostral to where the cerebellar peduncles merge with the cer-
ebellum. After the trigeminal motor neurons exit the pons, they pass
into the canal of the trigeminal nerve in the petrosal portion of the
temporal bone where the trigeminal ganglion also is located.1 Thus,
lesions affecting the cerebellopontine angle or petrosal portion of the
temporal bone can cause MM atrophy.
Although unilateral MM atrophy often is caused by conditions
associated with a poor prognosis, MRI did not identify a lesion in >25%
of our cases. Magnetic resonance imaging did not show any abnormali-
ties in the pons or along the anatomical pathway of the trigeminal
nerve. It is unclear whether or not dogs in this group all were affected
by the same underlying pathology or a more heterogeneous group of
disorders. Potential underlying conditions could be inflammatory, trau-
matic, neoplastic, degenerative, or idiopathic in nature. Although
Staffordshire Bull Terriers and Labrador Retrievers most often were
affected by this clinical presentation, it is unclear if a true breed predis-
position exists. Unilateral MM atrophy theoretically could be caused by
disorders affecting the trigeminal nerve or the MMs themselves, such
as masticatory myositis.2,15 In half of affected cases, neurological exami-
nation did however identify abnormalities suggestive of dysfunction of
other branches of the trigeminal nerve or dysfunction of neural struc-
tures in close proximity to the trigeminal nerve. Additionally, testing for
type 2M antibodies indicative of masticatory myositis was negative in
all tested cases. These findings could suggest that unilateral MM atro-
phy without abnormalities observed on MRI could represent a neuropa-
thy instead of a myopathy in some cases. Unilateral MM atrophy as the
sole clinical sign in combination with normal MRI findings is a rare clini-
cal presentation in humans.16–18 This presentation is considered benign
and is referred to as pure trigeminal motor neuropathy. It is character-
ized by trigeminal motor paralysis without sensory trigeminal distur-
bances or involvement of other cranial nerves.16–18 Although this
clinical presentation is similar to that observed in the dogs of our study,
several animals had clinical signs suggestive of trigeminal sensory neu-
ropathy and involvement of cranial nerves in close proximity to the tri-
geminal nerve. It is possible that MRI was not sensitive enough to
detect small lesions along the anatomical pathway of the trigeminal
nerve. Thus, it remains uncertain if unilateral MM atrophy in dogs with-
out abnormalities on MRI represents a benign or malignant condition.
This uncertainty is reflected by the fact that 1 dog was euthanized at
the time of diagnosis, approximately half of the dogs did not receive
any specific type of treatment, and a variety of treatments were recom-
mended in the remaining dogs. With the exception of 1 dog, neurologi-
cal deterioration was not observed in any of the dogs in which MRI
failed to identify an underlying cause for unilateral MM atrophy. The
dog that was euthanized for neurological deterioration had received
radiotherapy and developed decreased mentation and nonambulatory
tetraparesis 38 months after MRI was performed. Unfortunately, no
further diagnostic tests were performed at the time of euthanasia. This
dog may have developed neurological signs because of trigeminal nerve
pathology, but it also is possible that this dog could have developed an
unrelated neurological disorder or suffered from late effect radiation
toxicity, which is characterized by persistent progressive neurologic
signs >6 months after radiation treatment without imaging evidence of
tumor progression.19 It remains unclear if this dog was euthanized for
reasons related or unrelated to its clinical presentation for unilateral
MM atrophy. A study evaluating the outcome of dogs with suspected
TNSTs after stereotactic radiotherapy suggested that late radiation
effects cannot always be distinguished from tumor progression.7 Most
of the remaining treated dogs received prednisolone with or without
additional chemotherapy. It can be questioned however if: (1) medical
treatment is necessary in these dogs, (2) benefits of empirical medical
treatment outweigh costs and potential adverse effects; and (3) if treat-
ment with prednisolone complicates assessment of clinical progression.
The adverse effects of prednisolone are well characterized and include
muscle atrophy, which often predominantly affects the temporalis mus-
cles.20,21 For these reasons and because none of the dogs that did not
receive medical treatment experienced progression of neurological defi-
cits, we currently do not recommend starting empirical treatment when
MRI does not identify an underlying cause for unilateral MM atrophy.
Our study had several limitations. Although previously published
imaging criteria were used, diagnoses were not confirmed by histopa-
thology. It has been determined previously that histopathology is
required for accurate diagnosis because the MRI appearance of TNST
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can be mimicked by nonneoplastic conditions such as trigeminal neuri-
tis.22 Assessment of outcome was complicated by the fact that some
clients elected euthanasia without attempting further treatment, by
variation in treatment protocols for the remaining dogs, by variable
clinical presentations, and by different imaging findings among dogs
within the same diagnosis category. Assessment of outcome was fur-
ther complicated by the retrospective nature of the study. Only dogs
assessed for further evaluation of facial asymmetry caused by unilat-
eral MM atrophy were included. Dogs that had unilateral MM atrophy
as part of a more complex clinical presentation were not included. Our
study therefore does not include all possible underlying causes for
unilateral MM atrophy in dogs, but rather those disorders associated
with unilateral MM atrophy as a predominant clinical sign.
Despite these limitations, our study had several new clinically
relevant findings. Unilateral MM atrophy is an uncommon clinical
presentation associated with facial asymmetry, altered facial aes-
thetics, and a variable prevalence of additional neurological deficits.
Historically, unilateral MM atrophy has been associated with a poor
prognosis and has been assumed to be most commonly caused by
trigeminal nerve neoplasia. Although our study confirmed that
pTNST was the most common cause, unilateral MM atrophy is not
pathognomonic for PNST and alternative etiologies are implicated in
>50% of cases. More than 25% of dogs with unilateral MM atrophy
have no lesions detected on MRI and generally do not experience
further disease progression. Although additional studies are neces-
sary to determine the underlying pathology in this last group of
dogs, this finding illustrates that unilateral MM atrophy can be
caused by a variety of malignant and benign conditions. This obser-
vation emphasizes the importance of performing a complete neuro-
logical examination and advanced diagnostic tests in dogs
presenting with unilateral MM atrophy.
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